City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...

I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...

Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...

Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...

The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial ...

Sentynl Therapeutics secures FDA priority review for CUTX-101, a potential first treatment for Menkes disease. Supported by ...

Administration (FDA) approved an update to the US Prescribing Information (USPI) for Pyrukynd (mitapivat) for the treatment ...

Chinese researchers use AI to identify HG9-91-01, a potential neuroprotective treatment for glaucoma. The molecule shows ...

Patrick Branch, head of Japan and APAC business development at Nxera Pharma, Japan’s most innovative and nimble biopharma ...

Immedica Pharma acquires Marinus Pharmaceuticals for $151 million, gaining the rare disease treatment Ztalmy and expanding ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...